Briefing
Whole genome-based ultrasensitive circulating tumor DNA clearance as a biomarker of exceptional outcomes with enfortumab vedotin and pembrolizumab in urothelial carcinoma: Preliminary real-world results.
In 27 people with urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab, 22 of whom had muscle-invasive bladder cancer, Next Personal Dx ctDNA clearance occurred in 11 of the evaluable patients and was described as tracking with clinical and radiographic response.
- Design: Abstract 866
- Assay: NeXT Personal